Reuters logo
BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP
May 2, 2017 / 5:20 AM / 7 months ago

BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP

May 2 (Reuters) - Ablynx Nv:

* Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

* A total of 145 patients have been enrolled

* Data from this Phase III study will be reported in second half of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below